Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
acute kidney injury 2 nephrologydiseases
chronic kidney disease 4 nephrologydiseases
kidney failure 1 nephrologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
acute kidney injury 3068 populations and cell-derived factors – secreted growth factors, microvesicles and exosomes – in acute kidney injury models, suggesting a renal regenerative effect of cell-based therapies. Importantly, these preclinical
acute kidney injury 23182 anti-fibrotic and proangiogenic properties ([49]). Clinical trials with MSCs have been initiated for acute kidney injury and transplantation ([7]), but application of MSCs in the setting of CKD has not yet taken place. There
chronic kidney disease 72 Title: Disease Models & MechanismsCell-based therapies for experimental chronic kidney disease : a systematic review and meta-analysisDiana A. PapazovaNynke R. OosterhuisHendrik GremmelsArianne van
chronic kidney disease 361 3/2015Publication date (epub): 1/2015AbstractCell-based therapy is a promising strategy for treating chronic kidney disease (CKD) and is currently the focus of preclinical studies. We performed a systematic review and meta-analysis
chronic kidney disease 2297 therapeutic interventions in a clinical setting.INTRODUCTIONWorldwide, the number of individuals with chronic kidney disease (CKD) is rising, mainly owing to a dramatic increase in atherosclerosis and type-2 diabetes ([45]).
chronic kidney disease 6849 section.TRANSLATIONAL IMPACTClinical issueDespite elucidation of major factors involved in the progression of chronic kidney disease (CKD) and development of better treatments, the number of individuals with end-stage kidney disease
kidney failure 30803 [Tiab] OR ‘kidney disease’ [Tiab] OR ‘renal injury’ [Tiab] OR ‘renal failure’ [Tiab] OR ‘ kidney failure ’ [Tiab] OR ‘nephropathy’ [Tiab] OR ‘renal disease’ [Tiab] OR ‘renal function’ [Tiab] OR

You must be authorized to submit a review.